SLC5A1 and Hyperglycemia: Therefore,gliflozins have received increasing attention, prompting extensivestructure–activity relationship studies and optimization approaches.The discovery that intestinal SGLT-1 inhibition can provide a novelopportunity to control hyperglycemia, through a multifactorial mechanism,recently encouraged the design of low adsorbable inhibitors selectivelydirected to the intestinal SGLT-1 subtype as well as of dual SGLT-1/SGLT-2inhibitors, representing a compelling strategy to identify new antidiabeticdrug candidates.